Zentalis Pharmaceuticals (ZNTL) Accumulated Depreciation & Amortization (2022 - 2025)
Zentalis Pharmaceuticals (ZNTL) has 4 years of Accumulated Depreciation & Amortization data on record, last reported at $160000.0 in Q3 2025.
- For Q3 2025, Accumulated Depreciation & Amortization fell 50.16% year-over-year to $160000.0; the TTM value through Sep 2025 reached $160000.0, down 50.16%, while the annual FY2024 figure was $1.3 million, 7.14% down from the prior year.
- Accumulated Depreciation & Amortization reached $160000.0 in Q3 2025 per ZNTL's latest filing, roughly flat from $160000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $1.4 million in Q4 2022 and bottomed at $160000.0 in Q2 2025.
- Average Accumulated Depreciation & Amortization over 4 years is $611266.7, with a median of $344000.0 recorded in 2022.
- Peak YoY movement for Accumulated Depreciation & Amortization: increased 4.65% in 2023, then plummeted 69.49% in 2024.
- A 4-year view of Accumulated Depreciation & Amortization shows it stood at $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then decreased by 7.14% to $1.3 million in 2024, then plummeted by 87.69% to $160000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $160000.0 in Q3 2025, $160000.0 in Q2 2025, and $262000.0 in Q1 2025.